652 related articles for article (PubMed ID: 17548745)
21. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.
Wittorf A; Sickinger S; Wiedemann G; Klingberg S
Arch Clin Neuropsychol; 2008 May; 23(3):271-82. PubMed ID: 18272323
[TBL] [Abstract][Full Text] [Related]
22. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.
Goldberg TE; Weinberger DR
J Clin Psychiatry; 1996; 57 Suppl 9():62-5. PubMed ID: 8823353
[TBL] [Abstract][Full Text] [Related]
23. [Tolerance of neuroleptics, deficit syndrome and cognitive functions].
Kahn JP
Encephale; 1996 Jun; 22 Spec No 2():49-54. PubMed ID: 8767043
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneity of treatment effects in schizophrenia.
Stroup TS
Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
[TBL] [Abstract][Full Text] [Related]
25. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological treatment of cognition in schizophrenia: an idea whose method has come.
Harvey PD; Cornblatt BA
Am J Psychiatry; 2008 Feb; 165(2):163-5. PubMed ID: 18245181
[No Abstract] [Full Text] [Related]
27. Comparing symptom response among antipsychotic medications in CATIE.
Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
J Clin Psychopharmacol; 2013 Feb; 33(1):123-6. PubMed ID: 23288232
[No Abstract] [Full Text] [Related]
28. Cognitive impairment as a target for pharmacological treatment in schizophrenia.
Davidson M; Keefe RS
Schizophr Res; 1995 Sep; 17(1):123-9. PubMed ID: 8541245
[No Abstract] [Full Text] [Related]
29. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.
Weiss EM; Bilder RM; Fleischhacker WW
Psychopharmacology (Berl); 2002 Jun; 162(1):11-7. PubMed ID: 12107611
[TBL] [Abstract][Full Text] [Related]
30. Treatment of cognitive deficits in schizophrenia.
Bowie CR; Harvey PD
Curr Opin Investig Drugs; 2006 Jul; 7(7):608-13. PubMed ID: 16869112
[TBL] [Abstract][Full Text] [Related]
31. Deficits in neurocognition, theory of mind, and social functioning in patients with schizophrenic disorders: are they related?
Bâ MB; Zanello A; Varnier M; Koellner V; Merlo MC
J Nerv Ment Dis; 2008 Feb; 196(2):153-6. PubMed ID: 18277224
[TBL] [Abstract][Full Text] [Related]
32. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls.
Ahn YM; Lee KY; Kim CE; Kim JJ; Kang DY; Jun TY; Choi JS; Chung IW; Kim SH; Hwang SS; Kim YS
J Clin Psychopharmacol; 2009 Apr; 29(2):117-23. PubMed ID: 19512972
[TBL] [Abstract][Full Text] [Related]
33. [Value of brain imaging in assessment of cognitive symptoms. Cognitive and emotional impact of antipsychotic drug treatment]].
Martinot JL; Peretti CS
Encephale; 2006 Jan; 32 Pt 2():S3-5. PubMed ID: 16800076
[No Abstract] [Full Text] [Related]
34. Gender differences in cognition in schizophrenia.
Perlick D; Mattis S; Stastny P; Teresi J
Schizophr Res; 1992 Oct; 8(1):69-73. PubMed ID: 1358186
[TBL] [Abstract][Full Text] [Related]
35. Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
Weiss E; Kemmler G; Fleischhacker WW
Arch Gen Psychiatry; 2002 Jun; 59(6):572-3; author reply 573-5. PubMed ID: 12044210
[No Abstract] [Full Text] [Related]
36. [Schizophrenia and cognition: long-standing and current issues].
Azorin JM; Da Fonseca D; Fakra E
Encephale; 2011 Dec; 37 Suppl 2():S93-4. PubMed ID: 22212848
[No Abstract] [Full Text] [Related]
37. Predictors of longitudinal changes in schizophrenia: the role of processing speed.
Sánchez P; Ojeda N; Peña J; Elizagárate E; Yoller AB; Gutiérrez M; Ezcurra J
J Clin Psychiatry; 2009 Jun; 70(6):888-96. PubMed ID: 19422757
[TBL] [Abstract][Full Text] [Related]
38. All antipsychotics are equal, but some are more equal than others.
Volavka J; Citrome L
J Clin Psychiatry; 2009 Mar; 70(3):429-30. PubMed ID: 19317959
[No Abstract] [Full Text] [Related]
39. [Typical and atypical antipsychotics: Is there a difference in their influence on neurocognition?].
Faber G; van Gool AR; Smid HG; Wiersma D; van den Bosch RJ
Tijdschr Psychiatr; 2011; 53(2):107-17. PubMed ID: 21319067
[TBL] [Abstract][Full Text] [Related]
40. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.
Keefe RS; Goldberg TE; Harvey PD; Gold JM; Poe MP; Coughenour L
Schizophr Res; 2004 Jun; 68(2-3):283-97. PubMed ID: 15099610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
